STOCK TITAN

Irhythm Technologies Inc Stock Price, News & Analysis

IRTC Nasdaq

Welcome to our dedicated page for Irhythm Technologies news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on Irhythm Technologies stock.

iRhythm Technologies Inc (IRTC) delivers innovative digital cardiac monitoring solutions through its Zio System, combining wearable biosensors with AI-powered analytics. This page provides investors and healthcare professionals with direct access to official company announcements, including product updates, clinical research findings, and strategic developments shaping the future of ambulatory ECG diagnostics.

Discover timely updates on regulatory milestones, partnership agreements, and financial performance. Our curated collection ensures you stay informed about IRTC's advancements in extended cardiac monitoring technology and its growing role in preventive cardiology.

Explore press releases covering FDA clearances, peer-reviewed study validations, and operational expansions. All content is organized to highlight iRhythm's commitment to improving arrhythmia detection through cloud-connected devices and machine learning algorithms.

Bookmark this page for streamlined access to verified information about IRTC's market leadership in digital health solutions. Check back regularly to monitor how iRhythm continues to redefine patient care through clinically validated, data-driven insights.

Rhea-AI Summary
iRhythm Technologies (NASDAQ:IRTC) has launched its Zio® ECG Recording and Analysis System in Japan, marking its entry into the world's second-largest ambulatory cardiac monitoring market. The system offers up to 14 days of continuous ECG monitoring, powered by PMDA-approved AI algorithms capable of detecting 13 arrhythmia types. The Zio monitor features a lightweight, comfortable patch design with 99% patient compliance and analyzable data rates. The system combines AI technology with human expertise through certified cardiographic technician review, achieving 99% physician agreement. Japan's market, with approximately 1.6 million tests prescribed annually, represents a significant opportunity as the country faces increasing arrhythmia prevalence in its aging population. The nationwide rollout is expected to complete by July 2025, distributed exclusively through Senko Medical Instrument.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
iRhythm Technologies (NASDAQ: IRTC) reported strong Q1 2025 financial results with revenue of $158.7 million, up 20.3% year-over-year. The company achieved a gross margin of 68.8%, representing a 250-basis point increase from Q1 2024. Despite revenue growth, iRhythm posted a net loss of $30.7 million, though improved from $45.7 million loss in Q1 2024. Key operational highlights include expansion into Japan, strong Zio AT demand in the US and UK, and positive clinical study results showing superior arrhythmia detection rates. The company maintains a strong financial position with $520.6 million in cash and marketable securities. For full-year 2025, iRhythm raised guidance, projecting revenue between $690-700 million and adjusted EBITDA margin of 7.5-8.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

iRhythm Technologies, a digital health care company specializing in disease detection, prevention, and prediction solutions, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference.

The company's management team is set to deliver their presentation on Tuesday, May 13, 2025, at 3:40 p.m. Pacific Time (6:40 p.m. Eastern Time). Investors and interested parties can access both the live presentation and its archived version through the "Events & Presentations" section on iRhythm's investor website at investors.irhythmtech.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
Rhea-AI Summary

iRhythm Technologies (NASDAQ:IRTC) presented new real-world data from the AVALON study at HRS2025, demonstrating the clinical superiority of their Zio long-term continuous monitoring (LTCM) service. The study analyzed 428,707 commercially insured patients, showing Zio LTCM achieved:

- Highest diagnostic yield (26.5%) compared to other monitoring services
- 2.04x higher likelihood of arrhythmia diagnosis vs. Holter monitors
- Lowest likelihood of repeat testing within 180 days
- Reduced cardiovascular events risk within 1 year

The Zio LTCM service includes a patch-based ECG monitor capturing 14 days of continuous data and the ZEUS system with FDA-cleared AI algorithm. The study expands on previous CAMELOT findings in Medicare patients, now confirming benefits in younger, commercially insured populations (mean age: 46 years).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Summary

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prevention, and prediction solutions, has scheduled its first quarter 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call with management at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both live and archived versions of the conference call through the 'Quarterly Results' section on iRhythm's investor website at investors.irhythmtech.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
-
Rhea-AI Summary

iRhythm Technologies (NASDAQ:IRTC) has released its 2024 Corporate Sustainability Report, showcasing the company's progress in building a sustainable and inclusive future. The report focuses on four key pillars:

  • Quality and Sustainable Technology Innovation: Enhanced quality systems, improved EHR integration, secured strategic licensing, and formed an AI Governance Committee
  • Access and Health Equity: Expanded to four European countries and received Japanese regulatory approval for Zio® 14-day ECG monitoring system
  • Workforce and Inclusion: Refreshed core values, revised code of conduct, and introduced new employee recognition programs
  • Environmental Impact: Completed Scope 3 emissions inventory, achieved 89.5% landfill waste diversion, obtained ISO 14001:2015 certification, and was named to Newsweek's America's Greenest Companies 2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Rhea-AI Summary

Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer. King brings over 30 years of experience in healthcare and technology, having previously led companies like Affymetrix and Thomson Reuters Healthcare.

The company, focused on precision brain mapping and targeting technologies, is developing advanced functional connectivity MRI processing techniques. Under King's leadership, Turing Medical plans to launch a clinical trial of its PACE Therapy for Treatment Resistant Depression, integrating their Bullsai platform with minimally invasive neuromodulation therapy.

Recent company achievements include FDA 510(k) clearance for the Bullsai platform, an automated cloud-based system for neurosurgical planning, and successful marketing of FIRMM and FIRMM-pix MRI motion monitoring software solutions since 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary

iRhythm Technologies (NASDAQ:IRTC) presented significant findings from two large real-world studies at ACC.25, analyzing over 1.1 million patients using Zio® long-term continuous monitoring (LTCM) devices. The research revealed critical limitations in traditional 24-48 hour Holter monitoring.

Key findings show that 64% of actionable arrhythmias in patients with daily symptoms went undetected in the first 48 hours of monitoring. Non-daily symptom patients showed higher arrhythmia yield (80.9%) compared to daily-symptom patients (69.1%). The study also found that less than 20% of patients documented symptoms coinciding with arrhythmic episodes, and over half of atrial fibrillation cases were asymptomatic.

The research challenges conventional monitoring approaches and supports the benefits of Zio LTCM's extended 14-day monitoring period. With approximately 16 million Americans experiencing arrhythmias and undiagnosed atrial fibrillation costing the U.S. $3 billion annually, these findings have significant implications for clinical care and payer policies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Summary

iRhythm Technologies (NASDAQ: IRTC) reported strong Q4 2024 results with revenue of $164.3 million, up 24.0% year-over-year, and improved gross margin of 70.0%. The company narrowed its net loss to $1.3 million, a $37.4 million improvement from Q4 2023.

For full-year 2024, revenue grew 20.1% to $591.8 million with gross margin reaching 68.9%. Annual net loss improved to $113.3 million from $123.4 million in 2023. The company maintained a strong cash position of $535.6 million at year-end.

Looking ahead, iRhythm provided 2025 guidance projecting revenue between $675-685 million and adjusted EBITDA margin of 7.0-8.0%. The company highlighted record new account onboarding and successful expansion into international markets, while maintaining positive cash flow for three consecutive quarters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
Rhea-AI Summary

iRhythm Technologies (NASDAQ:IRTC) has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after market close. The digital health care company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors and interested parties can access both live and archived versions of the conference call through the 'Quarterly Results' section on the company's investor website at investors.irhythmtech.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences earnings

FAQ

What is the current stock price of Irhythm Technologies (IRTC)?

The current stock price of Irhythm Technologies (IRTC) is $131.12 as of May 2, 2025.

What is the market cap of Irhythm Technologies (IRTC)?

The market cap of Irhythm Technologies (IRTC) is approximately 3.4B.
Irhythm Technologies Inc

Nasdaq:IRTC

IRTC Rankings

IRTC Stock Data

3.38B
31.48M
0.82%
112.44%
9.38%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
San Francisco